Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Cancers|July 12, 2025
Contemporary Outcomes of Robot-Assisted Partial Nephrectomy: Results from Two European Referral InstitutionsFrancesco Barletta, Nicola Frego, Mario de Angelis, et al.
World Journal of Urology|November 29, 2019
Artificial intelligence and robotics: a combination that is changing the operating roomIulia Andras, Elio Mazzone, Fijs W B van Leeuwen, et al.
European Urology|March 3, 2021
The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder CancerGiuseppe Rosiello, Pietro Piazza, Victor Tames, et al.
Acta Oncologica (Stockholm, Sweden)|July 30, 2025
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?Alexander Decruyenaere, Gennigens Christine, Rottey Sylvie, et al.
Future Oncology (London, England)|May 2, 2020
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomyPiet Dirix, Michiel Strijbos, Tom Van den Mooter, et al.
Urologic Oncology|February 7, 2016
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use programCharles Van Praet, Sylvie Rottey, Fransien Van Hende, et al.
Clinical Genitourinary Cancer|March 5, 2017
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?Charles Van Praet, Sylvie Rottey, Fransien Van Hende, et al.
Journal of Robotic Surgery|November 15, 2022
Long-term oncologic outcomes of robot-assisted radical cystectomy: update series from a high-volume robotic center beyond 10 years of follow-upCarlo A Bravi, Pietro Piazza, Elio Mazzone, et al.
European Urology Oncology|April 22, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform TrialAlessio Crippa, Bram De Laere, Andrea Discacciati, et al.
Nature Medicine|August 20, 2024
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trialBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Pageof 5